Prenetics Global Limited (NASDAQ: PRE) is a Consumer Defensive company in the Packaged Foods industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
24.19
+0.00%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -4.16 | Insider Own | 8.42% | Shs Outstand | 17.00M | Perf Week | 3.07% |
| Market Cap | 411.24M | Forward P/E | - | EPS next Y | -1.65 | Insider Trans | 3.34% | Shs Float | 12.63M | Perf Month | 28.94% |
| Enterprise Value | 389.24M | PEG | - | EPS next Q | -0.73 | Inst Own | 12.41% | Short Float | 4.73% | Perf Quarter | 18.00% |
| Income | -67.00M | P/S | 2.88 | EPS this Y | 16.83% | Inst Trans | - | Short Ratio | 2.55 | Perf Half Y | 14.37% |
| Sales | 143.00M | P/B | 2.55 | EPS next Y | 52.43% | ROA | -44.00% | Short Interest | 598.22K | Perf YTD | 53.59% |
| Book/sh | 9.47 | P/C | 17.14 | EPS next 5Y | - | ROE | -49.17% | 52W High | 27.24 -11.20% | Perf Year | 125.65% |
| Cash/sh | 1.41 | P/FCF | - | EPS past 3/5Y | - | ROIC | -42.66% | 52W Low | 10.20 137.16% | Perf 3Y | 209.34% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 91.99% 7.20% | Gross Margin | 62.61% | Volatility | 7.74% 7.36% | Perf 5Y | -78.60% |
| Dividend TTM | - | EV/Sales | 2.72 | EPS Y/Y TTM | -14.29% | Oper. Margin | -35.20% | ATR (14) | 1.63 | Perf 10Y | - |
| Dividend Ex-Date | Feb 17, 2016 | Quick Ratio | 3.66 | Sales Y/Y TTM | 361.29% | Profit Margin | -47.43% | RSI (14) | 55.75 | Recom | 2.00 |
| Dividend Gr. 3/5Y | -35.09% -21.51% | Current Ratio | 4.04 | EPS Q/Q | 35.37% | SMA20 | -0.63% | Beta | 0.31 | Target Price | 37.50 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 155.56% | SMA50 | 14.05% | Rel Volume | 0.56 | Prev Close | 24.19 |
| Employees | 98 | LT Debt/Eq | 0.02 | Earnings | Nov 09 | SMA200 | 28.20% | Avg Volume | 223.19K | Price | 24.19 |
| IPO Date | Jul 16, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 36.90% -6.74% | Net Debt/EBITDA | 0.93 | Volume | 123,888 | Change | 0.00% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-17-26 | Initiated | Craig-Hallum | Buy | $40 |
| Jul-15-26 | Reiterated | Lake Street | $29 → $35 | |
| Feb-11-26 | Initiated | Roth Capital | Buy | $36 |
Latest News· Times ET
Sep-15-26
Sep-15-2606:25AM
Aug-27-26
Aug-27-2609:43AM
Aug-26-26
Aug-26-2604:38AM
Aug-24-26
Aug-22-26
Aug-20-26
Aug-20-2605:00AM
Aug-18-26
Aug-17-26
Aug-17-2604:30AM
Aug-07-26
Aug-07-2604:30AM
Aug-04-26
Jul-23-26
02:22AM
Jul-15-26
Company
As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.
Ownership
Total institutional ownership12.41%
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 143 | 92 | 31 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 54 | 44 | 15 | — | — | — | — | — | |
| Gross Profit | 89 | 49 | 15 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 131 | 80 | 55 | — | — | — | — | — | |
| Research and Development | 4 | 5 | 11 | — | — | — | — | — | |
| Other Operating Expense | 4 | 2 | -2 | — | — | — | — | — | |
| Operating Income | -50 | -38 | -48 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -22 | 2 | -9 | — | — | — | — | — | |
| Net Income Before Taxes | -71 | -36 | -58 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -8 | — | — | — | — | — | |
| Consolidated Net Income | -67 | -38 | -46 | — | — | — | — | — | |
| Net Income From Continuing Operations | -71 | -36 | -50 | — | — | — | — | — | |
| Net Income | -67 | -38 | -46 | — | — | — | — | — | |
| EPS (Recurring) | -4.16 | -2.68 | -3.64 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.16 | -2.68 | -3.64 | — | — | — | — | — | |
| EPS (Diluted) | -4.16 | -2.68 | -3.64 | — | — | — | — | — | |
| EBITDA | -64 | -32 | -52 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.88 | 2.40 | 2.43 | — | — | — | — | — | |
| Gross Margin | 62.24 | 53.26 | 48.39 | — | — | — | — | — | |
| Operating Margin | -34.97 | -41.30 | -154.84 | — | — | — | — | — | |
| Net Margin | -46.85 | -41.30 | -148.39 | — | — | — | — | — | |
| Shares Outstanding | 17 | 14 | 13 | — | — | — | — | — | |
| Market Capitalization | 411 | 221 | 75 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Leogrande Hudson Blake | Director | Sep 04 '26 | Option Exercise | 0.00 | 2,000 | 0 | 6,001 | Sep 04 |
| Rosin Brian J | CFO of IM8 (US) LLC | Aug 25 '26 | Buy | 22.80 | 5,100 | 116,280 | 23,100 | Aug 26 |
| Rosin Brian J | CFO of IM8 (US) LLC | Aug 24 '26 | Buy | 21.19 | 18,000 | 381,420 | 18,000 | Aug 26 |
| Yeung Danny Sheng Wu | Chief Executive Officer | Aug 24 '26 | Buy | 21.23 | 17,181 | 364,673 | 112,416 | Aug 24 |
| Lo Hoi Chun | Chief Financial Officer | Aug 21 '26 | Option Exercise | 0.00 | 569,580 | 52 | 566,013 | Aug 24 |
| Yeung Danny Sheng Wu | Chief Executive Officer | Aug 20 '26 | Option Exercise | 0.00 | 863,248 | 86 | 137,647 | Aug 24 |
| Yeung Danny Sheng Wu | Chief Executive Officer | Aug 20 '26 | Buy | 18.31 | 7,500 | 137,325 | 95,235 | Aug 24 |
| Leogrande Hudson Blake | Director | Aug 04 '26 | Option Exercise | 0.00 | 2,001 | 0 | 4,001 | Aug 05 |
| Leogrande Hudson Blake | Director | Jul 04 '26 | Option Exercise | 0.00 | 2,000 | 0 | 2,000 | Jul 07 |
| Cheng Yin Pan | Director | Jun 15 '26 | Option Exercise | 0.00 | 15,873 | 0 | 59,051 | Jun 16 |
| VANDERVEEN DAVID | Director | Jun 15 '26 | Option Exercise | 0.00 | 15,625 | 0 | 45,249 | Jun 16 |
| Desmet Laurie | EVP & COO, PartnerRe Ltd | Dec 21 '15 | Sale | 139.11 | 710 | 98,770 | 38,386 | Dec 22 |
| Hanratty Judith | Director | Oct 29 '15 | Sale | 139.30 | 2,336 | 325,405 | 5,601 | Nov 02 |
| SAUTTER REMY | Director | Sep 17 '15 | Option Exercise | 71.12 | 5,282 | 375,656 | 24,866 | Sep 18 |
| SAUTTER REMY | Director | Sep 17 '15 | Sale | 138.46 | 5,282 | 731,339 | 19,584 | Sep 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.